Hormon Reseptör Pozitif Meme Kanseri Tedavisinde Endokrin Direnç Mekanizmaları

Siegel, R. L., Miller, K. D., & Jemal, A. (Current Year). Cancer statistics. CA: A Cancer Journal for Clinicians.

Early Breast Cancer Trialists' Collaborative Group (EBCTCG). (2005). Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: an overview of the randomised trials. Lancet, 365(9472), 1687-1717.

Gradishar, W. J., et al. (Current Year). NCCN Guidelines® Insights: Breast Cancer, Version X. Journal of the National Comprehensive Cancer Network.

Burstein, H. J. (2012). The biology of endocrine resistance in breast cancer. Journal of the National Comprehensive Cancer Network, 10(Supplement 4), S1-S6.

Jordan, V. C. (2003). Tamoxifen: a most unlikely pioneering medicine. Nature Reviews Drug Discovery, 2(3), 205-213.

Smith, I. E., & Dowsett, M. (2003). Aromatase inhibitors in breast cancer. New England Journal of Medicine, 348(24), 2431-2442.

Howell, A., et al. (2002). Fulvestrant, a new treatment for breast cancer. Lancet, 360(9326), 57-61.

Osborne, C. K., & Schiff, R. (2011). Mechanisms of endocrine resistance in breast cancer. Annual Review of Medicine, 62, 233-247.

Harbeck N, Penault-Llorca F, Cortes J, Gnant M, Houssami N, Poortmans P, et al. Breast cancer. Nat Rev Dis Primers. 2019 Sep;5((1)):66. doi: 10.1038/s41572-019-0111-2.

Cardoso F, Senkus E, Costa A, Papadopoulos E, Aapro M, André F, et al. 4th ESO-ESMO International Consensus Guidelines for Advanced Breast Cancer (ABC 4) Ann Oncol. 2018 Aug;29((8)):1634–57. doi: 10.1093/annonc/mdy192.

Arpino, G., et al. (2004). Estrogen Receptor-Negative Conversion in Breast Cancer: Biological and Clinical Implications. Journal of the National Cancer Institute, 96(10), 727-732.

Davies, C., et al. (2012). The long-term effects of tamoxifen in women with breast cancer. Journal of the National Cancer Institute, 104(3), 199-209.

Musgrove, E. A., & Sutherland, R. L. (2009). Biological determinants of endocrine resistance in breast cancer. Nature Reviews Cancer, 9(9), 631-643.

Shou, J., et al. (2004). Cross-talk between Estrogen Receptor and HER2 in Breast Cancer. Journal of the National Cancer Institute, 96(23), 1735-1741.

Toy, W., et al. (2013). ESR1 mutation in metastatic breast cancer. Nature Genetics, 45(12), 1439-1444.

Jeselsohn, R., et al. (2014). ESR1 mutations in metastatic breast cancer patients: Clinical correlations and therapeutic implications. Oncologist, 19(5), 513-520.

Bidard, F. C., et al. (2022). Elacestrant versus standard endocrine therapy for ER+/HER2- advanced breast cancer with ESR1 mutations: results from the phase 3 EMERALD trial. Journal of Clinical Oncology, 40(28), 3246-3256.

Wang, Z., et al. (2006). A novel integral membrane estrogen receptor localized in mitochondria of breast cancer cells. Cancer Research, 66(22), 10793-10800.

Fruman, D. A., & Cantley, L. C. (2017). PI3K in Cancer: Aberrant Pathways and Therapeutic Opportunities. Cold Spring Harbor Perspectives in Medicine, 7(11), a026720.

Alzahrani, A. S. (2019). PI3K/Akt/mTOR Pathway in Cancer: An Update. Current Cancer Drug Targets, 19(5), 374-383.

Lemmon, M. A., & Schlessinger, J. (2010). Cell signaling by receptor tyrosine kinases. Cell, 141(7), 1117-1134.

Vivanco, I., & Sawyers, C. L. (2002). The phosphatidylinositol 3-kinase–AKT pathway in human cancer. Nature Reviews Cancer, 2(7), 489-501.

Laplante, M., & Sabatini, D. M. (2012). mTOR signaling in growth control and disease. Cell, 149(2), 274-293.

Paplomata, E., & O'Regan, R. M. (2014). The PI3K/AKT/mTOR pathway in breast cancer: targets, trials and biomarkers. Therapeutic Advances in Medical Oncology, 6(4), 150-166.

Presti, D., & Quaquarini, E. (2019). The PI3K/AKT/mTOR and CDK4/6 Pathways in Endocrine Resistant HR+/HER2− Metastatic Breast Cancer: Biological Mechanisms and New Treatments. Cancers, 11(9), 1242.

André, F., et al. (2019). Alpelisib for PIK3CA-mutated, HR+-HER2- advanced breast cancer. New England Journal of Medicine, 380(20), 1929-1940.

Baselga, J., et al. (2012). Everolimus in postmenopausal hormone-receptor–positive advanced breast cancer. New England Journal of Medicine, 366(6), 520-529.

Sansal, I., & Cantley, L. C. (2004). PI 3-kinase signaling in cancer. Journal of Clinical Oncology, 22(10), 1957-1965.

Parra-Palau, J. L., et al. (2016). AKT1 E17K mutation confers resistance to PI3Kα and PI3Kβ inhibition in breast cancer. Molecular Cancer Therapeutics, 15(7), 1709-1718.

Hortobagyi, G. N., et al. (2016). Everolimus plus exemestane in postmenopausal patients with HR+, HER2- advanced breast cancer: Overall survival results from BOLERO-2. Annals of Oncology, 27(1), 89-97.

Baselga, J., et al. (2020). Alpelisib plus fulvestrant for PIK3CA-mutated, HR+/HER2− advanced breast cancer: updated results from the SOLAR-1 study. Annals of Oncology, 31(7), 898-908.

FDA Approves Inavolisib with Palbociclib and Fulvestrant for Endocrine-Resistant, PIK3CA-Mutated, HR-Positive, HER2-Negative, Advanced Breast Cancer. U.S. Food and Drug Administration. 2024.

Turner, N. C., et al. (2023). Capivasertib in HR-positive, HER2-negative, advanced breast cancer. New England Journal of Medicine, 388(22), 2058-2070.

Goel, S., et al. (2018). Acquired resistance to cyclin D–CDK4/6 inhibitors in cancer. Nature Reviews Clinical Oncology, 15(7), 415-429.

Chen, P., et al. (2016). CDK4/6 Inhibition in Breast Cancer: Palbociclib, Ribociclib, and Abemaciclib. Journal of Hematology & Oncology, 9(1), 117.

Sherr, C. J., & McCormick, F. (2012). The RB and p53 pathways in cancer. Cancer Cell, 21(1), 10-21.

Musgrove, E. A., & Sutherland, R. L. (2009). Biological determinants of endocrine resistance in breast cancer. Nature Reviews Cancer, 9(9), 631-643.

O'Leary, B., et al. (2018). The molecular basis for CDK4/6 inhibitor resistance in ER-positive breast cancer. Nature Communications, 9(1), 2261.

Finn, R. S., et al. (2016). Palbociclib and Fulvestrant in Advanced Breast Cancer. New England Journal of Medicine, 375(20), 1925-1936.

Hortobagyi, G. N., et al. (2016). Ribociclib as First-Line Therapy for HR-Positive, HER2-Negative Advanced Breast Cancer. New England Journal of Medicine, 375(18), 1738-1748.

Sledge, G. W., et al. (2017). Abemaciclib as Monotherapy or in Combination with Fulvestrant in Women with HR+, HER2- Advanced Breast Cancer. Journal of Clinical Oncology, 35(15), 1718-1725.

Johnston, S. R. D., et al. (2023). Abemaciclib in High-Risk Early HR+, HER2− Breast Cancer. New England Journal of Medicine, 389(4), 312-326.

Im, S. A., et al. (2023). Ribociclib as Adjuvant Treatment in Patients with HR+/HER2− Early Breast Cancer: Primary Results from the Phase 3 NATALEE Trial. Journal of Clinical Oncology, 41(16_suppl), LBA500-LBA500.

Franco, J., et al. (2019). Targeting the CDK2 Pathway: A Promising Therapeutic Strategy in Breast Cancer. Cancers, 11(10), 1544.

Wander, S. A., et al. (2020). The molecular basis of CDK4/6 inhibitor resistance in breast cancer. npj Breast Cancer, 6(1), 34.